In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

Pregnant women with type 1 diabetes who used hybrid closed-loop insulin delivery with Control-IQ technology spent more time ...

After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

Continuous glucose monitoring reveals frequent dysglycaemia in very low birth weight infants nearing term age, with male sex ...

During a clinical trial, around 83% (10 out of 12) of patients who received a full dose of Zimislecel achieved complete ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Insulin-producing human pancreas cells can be manufactured with 3D printers, researchers reported at the International Transplant Congress underway in London.

Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved ...

Zimislecel, a novel stem cell therapy, has reportedly demonstrated promising results in an early-phase clinical trial ...

Researchers at a recent American Diabetes Association meeting reported that efsitora, experimental once-weekly insulin, was comparable to daily insulins in nearly a thousand adults with type 2 ...